Chengdu Zenitar Biomedical Technology Co., Ltd
Chengdu Zenitar Biomedical Technology Co., Ltd
Explore linked clinical trials.15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants | MB | Not yet recruiting | Phase 1 | 2026-09-09 | NCT07809217 | |
| Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets | Drug Interaction Research | Not yet recruiting | Phase 1 | 2026-08-19 | NCT07768111 | |
| Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 2 | 2026-08-14 | NCT07232290 | |
| A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis | MF | Recruiting | Phase 2 | 2026-08-13 | NCT07443306 | |
| A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis | MF | Recruiting | Phase 3 | 2026-08-13 | NCT07317700 | |
| A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis | MF,PMF,PPV-MF,PET-MF | Active, not recruiting | Phase 2 | 2026-08-12 | NCT06457425 | |
| Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China | Healthy Participants Study | Recruiting | Phase 1 | 2026-08-11 | NCT07757152 | |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, primary myelofibrosis | Not yet recruiting | Phase 2 | 2026-08-10 | NCT07750574 | |
| A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-02-06 | NCT06485219 | |
| A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-02-04 | NCT07193589 | |
| Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, neoplasm | Active, not recruiting | Phase 2 | 2026-02-04 | NCT05563844 | |
| A Clinical Study of ZL-85FA Tablets | Advanced Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-15 | NCT07339748 | |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2025-09-19 | NCT07011056 | |
| A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-04-10 | NCT06431243 | |
| Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2025-04-02 | NCT06484829 |